| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.03 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.082 | 0.03 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.04 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.04 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.079 | 0.04 |
| mRNA | nakiterpiosin | CTRPv2 | pan-cancer | AAC | -0.069 | 0.04 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.04 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.08 | 0.04 |